<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7501848\results\search\disease\results.xml">
  <result pre="doi: 10.1016/j.heliyon.2020.e05007e05007 : Review Article Nucleic acid-based therapy for coronavirus" exact="disease" post="2019 PiyushRavikantaRajarshiKeshavbChatterjeeAronicKhanRajnikhanrajni@gmail.comdâˆ—âˆ—RayShashikantshashikantray@mgcub.ac.ineâˆ—[a], [b], [c], [d], [e], âˆ—Corresponding author. shashikantray@mgcub.ac.in"/>
  <result pre="article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Abstract The coronavirus" exact="disease" post="2019 (COVID-19), the pandemic that originated in China has"/>
  <result pre="1 Introduction The world has already witnessed many viruses causing" exact="disease" post="outbreaks in various regions across the globe in the"/>
  <result pre="across the globe in the past two decades; such as" exact="Severe" post="acute respiratory syndrome coronavirus (SARS-CoV) epidemic in 2002â€&quot;2003 originated"/>
  <result pre="the globe in the past two decades; such as Severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) epidemic in 2002â€&quot;2003 originated in"/>
  <result pre="globe in the past two decades; such as Severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) epidemic in 2002â€&quot;2003 originated in China"/>
  <result pre="in the past two decades; such as Severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) epidemic in 2002â€&quot;2003 originated in China [1],"/>
  <result pre="pandemic in 2009, first reported in Spain [2], Middle East" exact="respiratory" post="syndrome (MERS) pandemic in 2012, first identified in Saudi"/>
  <result pre="in 2009, first reported in Spain [2], Middle East respiratory" exact="syndrome" post="(MERS) pandemic in 2012, first identified in Saudi Arabia"/>
  <result pre="2012, first identified in Saudi Arabia and the current [3]," exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) pandemic"/>
  <result pre="first identified in Saudi Arabia and the current [3], Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) pandemic in"/>
  <result pre="identified in Saudi Arabia and the current [3], Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) pandemic in 2019â€&quot;2020,"/>
  <result pre="in Saudi Arabia and the current [3], Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2 or COVID-19) pandemic in 2019â€&quot;2020, originating"/>
  <result pre="and nucleocapsid (N) in 5â€² to 3â€² direction of the" exact="viral" post="genome [7, 8, 9]. WHO officially designated this new"/>
  <result pre="viral genome [7, 8, 9]. WHO officially designated this new" exact="disease" post="as coronavirus disease-2019, i.e., COVID-19. To date, the virus"/>
  <result pre="years significant progress has been made in the understanding of" exact="viral" post="gene functioning, viral genomics, and target-based drug designing which"/>
  <result pre="has been made in the understanding of viral gene functioning," exact="viral" post="genomics, and target-based drug designing which have stimulated the"/>
  <result pre="the development of many therapeutic strategies capable of efficiently blocking" exact="viral" post="gene expression [11]. Among them, the nucleic acid-based therapeutic"/>
  <result pre="mode of action and has been designed to specifically arrest" exact="viral" post="disease progression [13]. The nucleic acid-based drugs have been"/>
  <result pre="of action and has been designed to specifically arrest viral" exact="disease" post="progression [13]. The nucleic acid-based drugs have been shown"/>
  <result pre="spectrum of anti-viral immunity in the body along with suppressing" exact="viral" post="replication and gene expression [14]. This phenomenon of producing"/>
  <result pre="acid-based therapeutic biomolecules have also shown some promising results in" exact="pulmonary" post="diseases [16]. Nucleic acid-based therapies, especially, RNA therapies including"/>
  <result pre="neutralize the crucial components of the virus-like specific mRNA molecules," exact="viral" post="proteins like E (envelope), M (membrane), or N (nucleocapsid),"/>
  <result pre="have been reported to show tropism towards the cells of" exact="respiratory" post="tracts which not only help in the entry of"/>
  <result pre="not only help in the entry of virus particles inside" exact="respiratory" post="tracts but it also helps to causes the infection"/>
  <result pre="inside respiratory tracts but it also helps to causes the" exact="infection" post="in the host cells [13]. The physiological function of"/>
  <result pre="of the lungs makes it highly exposed to pollutants and" exact="viral" post="particles from outside [13]. Due to this reason, lungs"/>
  <result pre="reason, lungs get susceptible to several diseases ranging from common" exact="viral infection" post="to lung cancer. Viruses that infect the respiratory tract"/>
  <result pre="lungs get susceptible to several diseases ranging from common viral" exact="infection" post="to lung cancer. Viruses that infect the respiratory tract"/>
  <result pre="susceptible to several diseases ranging from common viral infection to" exact="lung cancer." post="Viruses that infect the respiratory tract spread rapidly among"/>
  <result pre="common viral infection to lung cancer. Viruses that infect the" exact="respiratory" post="tract spread rapidly among the population due to their"/>
  <result pre="contact with the infected person or by droplets containing the" exact="viral" post="particles [13]. Currently, there is no therapeutic agent or"/>
  <result pre="[18], hydroxychloroquine, azithromycin, zinc sulfate and corticosteroids. Patients with severe" exact="infections" post="are treated by collateral care like ventilation and fluid"/>
  <result pre="could help in the control, prevention, and treatment of SARS-CoV-2" exact="infection" post="is an urgent need to save the entire globe"/>
  <result pre="entry of virus particles inside the host cells determines the" exact="viral" post="infectivity and pathogenicity [19]. The spike protein present on"/>
  <result pre="and small intestine, colon, thymus, bone marrow, lymph nodes, the" exact="brain" post="of the host cells [22]. The S1 subunit of"/>
  <result pre="kidneys, lungs, and intestines [25]. The immune response towards any" exact="disease" post="differs due to genetic variations from individual to individual."/>
  <result pre="due to genetic variations from individual to individual. The SARS-CoV-2" exact="infection" post="can be classified into two categories: initial (non-severe) and"/>
  <result pre="initial stages, macrophages and granulocytes mediate the inflammatory responses. SARS-CoV-2" exact="infection" post="in the respiratory system has been reported to activate"/>
  <result pre="and granulocytes mediate the inflammatory responses. SARS-CoV-2 infection in the" exact="respiratory" post="system has been reported to activate nuclear factor kappa-light-chain-enhancer"/>
  <result pre="the activation of pro-inflammatory cytokines, including interleukin-6 (IL-6), chemokines and" exact="tumor" post="necrosis factors (TNFs) [27]. Signal transducer and activator of"/>
  <result pre="via activation of the IL-6 amplifier (IL-6 Amp), leading to" exact="autoimmune" post="and multiple inflammatory diseases in the patients [28]. But"/>
  <result pre="in the patients [28]. But in severe cases, a powerful" exact="chronic" post="inflammation due to cytokine response from both immune and"/>
  <result pre="of epidemics, also efficient development of the vaccine may prevent" exact="infections" post="caused by highly transmittable pathogens. Since synthetic DNA and"/>
  <result pre="cells is that it imitates the protein synthesis during the" exact="infection" post="as the protein remains localized in the plasma membrane,"/>
  <result pre="the protein synthesis during the infection as the protein remains" exact="localized" post="in the plasma membrane, and protein modification processes like"/>
  <result pre="by ElectroporationDevice Inovio Pharmaceuticals ChAdOx1 Phase 1/Phase 2 (NCT04324606) Non-replicating" exact="viral" post="vector University of Oxford Pathogen-specific-aAPC Phase 1 (NCT04299724) Artificial"/>
  <result pre="lentiviral vector expressing synthetic minigene based on domains of selected" exact="viral" post="proteins Shenzhen Geno-Immune Medical Institute LV-SMENP-DC Phase 1 (NCT04276896)"/>
  <result pre="lentiviral vector expressing synthetic minigene based on domains of selected" exact="viral" post="proteins; administered with antigen-specific cytotoxic T lymphocytes (CTLs) Shenzhen"/>
  <result pre="(CTLs) Shenzhen Geno-Immune Medical Institute Ad5-nCoV Phase 1 (NCT04313127) Adenovirus" exact="type 5" post="vector that encodes S protein CanSino Biologicals Reference: ClinicalTrials.gov."/>
  <result pre="and miRNA have been used for the treatment of severe" exact="viral" post="infections including HIV-1 (human immunodeficiency virus) [36, 37]. The"/>
  <result pre="miRNA have been used for the treatment of severe viral" exact="infections" post="including HIV-1 (human immunodeficiency virus) [36, 37]. The infections"/>
  <result pre="for the treatment of severe viral infections including HIV-1 (human" exact="immunodeficiency" post="virus) [36, 37]. The infections caused by the H1N1"/>
  <result pre="viral infections including HIV-1 (human immunodeficiency virus) [36, 37]. The" exact="infections" post="caused by the H1N1 influenza A virus have been"/>
  <result pre="Further, it has been reported that the ribozyme inhibited the" exact="infection" post="of influenza virus both in vitro and in vivo"/>
  <result pre="modified ASOs (antisense oligonucleotides) were effective in suppression of the" exact="infection" post="by influenza A/PR8/34 (H1N1) virus [42]. ASOs were also"/>
  <result pre="be effective in the inhibition of RSV (respiratory syncytial virus)" exact="infection" post="[43]. 2.1 DNA vaccines Incorporation of a eukaryotic expression"/>
  <result pre="encodes for single or multiple antigens of interest into a" exact="bacterial" post="plasmid leads to the generation of DNA vaccines. The"/>
  <result pre="of the gene expressing cassette devoid of the backbone of" exact="bacterial" post="plasmid DNA. Several studies have reported that bacterial backbone"/>
  <result pre="backbone of bacterial plasmid DNA. Several studies have reported that" exact="bacterial" post="backbone resulted in a lower level of reporter transgene"/>
  <result pre="Several studies have reported that bacterial backbone resulted in a" exact="lower" post="level of reporter transgene expression compared with mice receiving"/>
  <result pre="to the inhibition resulted by the covalent attachment of the" exact="bacterial" post="backbone to the expression cassette [45]. DNA vaccines were"/>
  <result pre="that have been used so far as prophylactic vaccines against" exact="infectious" post="disease-causing pathogens [58]. The sequence of the specific antigen"/>
  <result pre="therapeutic approaches have been found to treat many of the" exact="pulmonary" post="diseases [79, 80]. Some of the molecules that have"/>
  <result pre="These therapeutic molecules have shown some promising effects against the" exact="viral infection" post="in the respiratory tract and to several other diseases"/>
  <result pre="therapeutic molecules have shown some promising effects against the viral" exact="infection" post="in the respiratory tract and to several other diseases"/>
  <result pre="shown some promising effects against the viral infection in the" exact="respiratory" post="tract and to several other diseases [82]. In a"/>
  <result pre="In a study conducted on the cultured Vero cells (kidney" exact="epithelial" post="cells) obtained from African green monkeys, inhibition of replication"/>
  <result pre="on the cultured Vero cells (kidney epithelial cells) obtained from" exact="African" post="green monkeys, inhibition of replication of virus along with"/>
  <result pre="[87]. TableÂ 2 Virus Type of RNAi Target of action" exact="Patent" post="Number Developing Organization SARS-CoV siRNA RdRP (RNA-dependent RNA polymerase)"/>
  <result pre="small RNAs, in the 1980s, called aptamers [88]. These are" exact="short" post="oligonucleotides (RNA or DNA) that specifically recognize and bind"/>
  <result pre="inhibited the function of Tat protein, which was essential for" exact="viral" post="replication as well as regulation of gene expression of"/>
  <result pre="well as regulation of gene expression of both cellular and" exact="viral" post="gene [93]. The binding of aptamers to their respective"/>
  <result pre="in a specific blockage of expression of detrimental genes. In" exact="lower" post="eukaryotes, some bacteria and viruses, several ribozymes promoting the"/>
  <result pre="To overcome this, in DNAzymes, these motifs are replaced with" exact="stable" post="DNA molecule. This provides enhanced biological stability and more"/>
  <result pre="was found that only two of them efficiently blocked the" exact="viral" post="replication in Vero cells by targeting the RNA polymerase,"/>
  <result pre="and release of the virus [127]. HCoV-NL63 S glycoprotein, a" exact="viral" post="entry protein, was found to be the target site"/>
  <result pre="siRNA. In virus-infected cells, these designed siRNAs significantly inhibited the" exact="infection" post="[128]. In another study, the synthesis of chimeric RNA-DNA"/>
  <result pre="that ribozymes (Rz) were found to be useful in inhibiting" exact="viral" post="replication up to 60% by using chimeric DNA-RNA hammerhead"/>
  <result pre="inhibit the replication of several viruses like the influenza virus," exact="respiratory" post="syncytial virus (RSV), and SARS-CoV by specifically targeting the"/>
  <result pre="etÂ al. used RNA aptamer ES15 to target nsP10 (nonstructural" exact="Protein" post="10) showed inhibiting viral replication in dose-dependent manner (IC50"/>
  <result pre="aptamer ES15 to target nsP10 (nonstructural Protein 10) showed inhibiting" exact="viral" post="replication in dose-dependent manner (IC50 = 1.2 nM) [132]."/>
  <result pre="vaccine, mRNA-1273, developed by the National Institute of Allergy and" exact="Infectious" post="Diseases in association with Moderna, is under phase1/phase 2"/>
  <result pre="mRNA-1273, developed by the National Institute of Allergy and Infectious" exact="Diseases" post="in association with Moderna, is under phase1/phase 2 of"/>
  <result pre="the antibodies against S protein may include the clearance of" exact="viral" post="load from the infected cells, and reduced bioavailability of"/>
  <result pre="Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2" exact="Infection" post="(COVID-19)â€� (trial identification number: NCT04283461), are in phase-1 and"/>
  <result pre="range has been estimated to be 25% less than of" exact="total" post="manufacturing costs, and up to 45% of labor and"/>
  <result pre="funding of $483M in April and $472M in July with" exact="total" post="funding of $955M approximately whereas another leading vaccine, ChAdOx1"/>
  <result pre="world population in regions like Africa, Southeast Asia, and Eastern" exact="Mediterranean" post="during the influenza pandemic in 2009 [160]. Based on"/>
  <result pre="stability and translation efficacy [161, 162]. The potential risk of" exact="infection" post="and insertion induced mutagenesis are minimized by mRNA based"/>
  <result pre="The mRNA vaccination may be detrimental due to local and" exact="systemic" post="inflammatory responses, possible development of autoreactive antibodies, persistence, and"/>
  <result pre="and pain at injection site are some of the solicited" exact="systemic" post="and local adverse effect that occurred in more than"/>
  <result pre="T cells [171, 172, 173]. The DNA drug product is" exact="stable" post="for a longer duration and can be deployed in"/>
  <result pre="reported that in human and large animals DNA vaccine causes" exact="lower" post="immunogenicity in comparison to inactivated vaccines, autoimmune responses, and"/>
  <result pre="DNA vaccine causes lower immunogenicity in comparison to inactivated vaccines," exact="autoimmune" post="responses, and DNA integration in the host genome, etc."/>
  <result pre="effects. Several nucleic acid-based vaccine against SARS-CoV-2 are in the" exact="primary" post="stages in the clinical trials. In summary, it can"/>
  <result pre="shown potential efficacy against several viruses including SARS-CoV and other" exact="chronic" post="diseases. In-vitro and in-vivo studies have proclaimed their importance"/>
  <result pre="can be an effective line of treatment for various other" exact="viral" post="diseases. Declarations Author contribution statement All authors listed have"/>
  <result pre="(H1N1) 2009 in SpainRevista espanola de salud publica845201056958821203720 3ZumlaA.I.MemishZ.A.Middle East" exact="respiratory" post="syndrome coronavirus: epidemic potential or a storm in a"/>
  <result pre="2009 in SpainRevista espanola de salud publica845201056958821203720 3ZumlaA.I.MemishZ.A.Middle East respiratory" exact="syndrome" post="coronavirus: epidemic potential or a storm in a teacup?Eur."/>
  <result pre="genome structure, replication, and pathogenesisJ.Â Med. Virol.924202041842331967327 5PandeyP.Targeting SARS-CoV-2 Spike" exact="Protein" post="of COVID-19 with Naturally Occurring Phytochemicals: an in Silico"/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg. Microb. Infect.912020221236 7WuF.AÂ new coronavirus associated"/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg. Microb. Infect.912020221236 7WuF.AÂ new coronavirus associated"/>
  <result pre="visiting WuhanEmerg. Microb. Infect.912020221236 7WuF.AÂ new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature5797798202026526932015508 8RajarshiK.ChatterjeeA.RayS.J.B.R.Combating COVID-19 with Mesenchymal Stem Cell"/>
  <result pre="WuhanEmerg. Microb. Infect.912020221236 7WuF.AÂ new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature5797798202026526932015508 8RajarshiK.ChatterjeeA.RayS.J.B.R.Combating COVID-19 with Mesenchymal Stem Cell Therapy2020e00467"/>
  <result pre="associated with human respiratory disease in ChinaNature5797798202026526932015508 8RajarshiK.ChatterjeeA.RayS.J.B.R.Combating COVID-19 with" exact="Mesenchymal" post="Stem Cell Therapy2020e00467 9RajarshiK.ChatterjeeA.RayS.BCG vaccination strategy implemented to reduce"/>
  <result pre="Is Evolving2020[cited 2020 August 1]; Available from:https://www.pharmaceutical-technology.com/news/coronavirus-a-timeline-of-how-the-deadly-outbreak-evolved/ 11GaleM.Translational control of" exact="viral" post="gene expression in eukaryotes6422000239280 12SridharanK.GogtayN.J.Therapeutic nucleic acids: current clinical"/>
  <result pre="J. Clin. Pharmacol.823201665967227111518 13AshaK.Advancements in nucleic acid based therapeutics against" exact="respiratory" post="viral infections8120196 14WongJ.P.Broad-spectrum and virus-specific nucleic acid-based antivirals against"/>
  <result pre="Clin. Pharmacol.823201665967227111518 13AshaK.Advancements in nucleic acid based therapeutics against respiratory" exact="viral" post="infections8120196 14WongJ.P.Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza22010791800"/>
  <result pre="of the art and future prospectsBlood92319987127369680338 16ChenJ.Nucleic acid-based therapeutics for" exact="pulmonary" post="diseasesAAPS PharmSciTech19820183670368030338490 17WuC.J.Inhibition of SARS-CoV replication by siRNAAntivir. Res.6512005454815652970"/>
  <result pre="Potential Drug against COVID-192020111 25XuZ.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.84202042042232085846 26WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the"/>
  <result pre="Drug against COVID-192020111 25XuZ.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.84202042042232085846 26WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging"/>
  <result pre="syndromeLancet Respir. Med.84202042042232085846 26WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe" exact="acute" post="respiratory syndrome coronavirusMicrobiol. Mol. Biol. Rev.694200563566416339739 27de WitE.SARS and"/>
  <result pre="Respir. Med.84202042042232085846 26WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute" exact="respiratory" post="syndrome coronavirusMicrobiol. Mol. Biol. Rev.694200563566416339739 27de WitE.SARS and MERS:"/>
  <result pre="Med.84202042042232085846 26WeissS.R.Navas-MartinS.Coronavirus pathogenesis and the emerging pathogen severe acute respiratory" exact="syndrome" post="coronavirusMicrobiol. Mol. Biol. Rev.694200563566416339739 27de WitE.SARS and MERS: recent"/>
  <result pre="receptor and cytokine release syndromeImmunity525202073173332325025 29ColafrancescoS.Targeting the immune system for" exact="pulmonary" post="inflammation and cardiovascular complications in COVID-19 patientsFront. Immunol.112020143932655577 30SurbatovicM.Immune"/>
  <result pre="release syndromeImmunity525202073173332325025 29ColafrancescoS.Targeting the immune system for pulmonary inflammation and" exact="cardiovascular" post="complications in COVID-19 patientsFront. Immunol.112020143932655577 30SurbatovicM.Immune response in severe"/>
  <result pre="36ZhouJ.RossiJ.Cell-typeâ€&quot;specific aptamer and aptamer-small interfering RNA conjugates for targeted human" exact="immunodeficiency" post="virus type 1 therapyJ.Â Invest. Med.6272014914919 37TrobaughD.W.KlimstraW.B.MicroRNA regulation of"/>
  <result pre="and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus" exact="type 1" post="therapyJ.Â Invest. Med.6272014914919 37TrobaughD.W.KlimstraW.B.MicroRNA regulation of RNA virus replication"/>
  <result pre="miR-3145 inhibits influenza A viruses replication by targeting and silencing" exact="viral" post="PB1 gene24012201516301639 40IngleH.The microRNA miR-485 targets host and influenza"/>
  <result pre="and influenza virus transcripts to regulate antiviral immunity and restrict" exact="viral" post="replication84062015ra126-ra126 41TangX.B.HobomG.LuoD.J.Ribozyme mediated destruction of influenza A virus in"/>
  <result pre="and synthesis of virus-specific proteins in MDCK cells25921990327330 43JairathS.Inhibition of" exact="respiratory" post="syncytial virus replication by antisense oligodeoxyribonucleotides3331997201213 44ChenZ.Y.Silencing of episomal"/>
  <result pre="by antisense oligodeoxyribonucleotides3331997201213 44ChenZ.Y.Silencing of episomal transgene expression by plasmid" exact="bacterial" post="DNA elements in vivoGene Ther.1110200485686415029228 45ChenZ.Y.Minicircle DNA vectors devoid"/>
  <result pre="DNA elements in vivoGene Ther.1110200485686415029228 45ChenZ.Y.Minicircle DNA vectors devoid of" exact="bacterial" post="DNA result in persistent and high-level transgene expression in"/>
  <result pre="Immunol.233201142142921530212 48HuangZ.H.Humoral and cellular immunogenecity of DNA vaccine based on" exact="hepatitis" post="B core gene in rhesus monkeysWorld J. Gastroenterol.71200110210611819742 49GonÃ§alvesA.J.Cooperation"/>
  <result pre="class of drugsNat. Rev.Drug. Discov.1310201475978025233993 58ZhangC.Advances in mRNA vaccines for" exact="infectious" post="diseasesFront. Immunol.10201959430972078 59SchlakeT.Developing mRNA-vaccine technologiesRNA Biol.91120121319133023064118 60CarralotJ.P.Polarization of immunity"/>
  <result pre="Med.1512017128049494 72WynantN.SantosD.Vanden BroeckJ.The evolution of animal Argonautes: evidence for the" exact="absence of" post="antiviral AGO Argonautes in vertebratesSci. Rep.712017923028835645 73HammondS.M.CaudyA.A.HannonG.J.Post-transcriptional gene silencing"/>
  <result pre="for lung diseasesPharmaceuticals (Basel)62201322325024275949 80ThankiK.Formulation of RNA interference-based drugs for" exact="pulmonary" post="delivery: challenges and opportunitiesTher. Deliv.910201873174930277138 81CheryJ.RNA therapeutics: RNAi and"/>
  <result pre="by directly targeting mRNA for degradation and indirectly inhibiting all" exact="viral" post="RNA transcription1005200327182723 85DeVincenzoJ.AÂ randomized, double-blind, placebo-controlled study of an"/>
  <result pre="randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against" exact="respiratory" post="syncytial virus10719201088008805 86DeVincenzoJ.Evaluation of the safety, tolerability and pharmacokinetics"/>
  <result pre="pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against" exact="respiratory" post="syncytial virus (RSV)7732008225231 87LiuC.Research and Development on Therapeutic Agents"/>
  <result pre="Redesign of Catalytic Function in Biopolymers1999Springer Berlin HeidelbergBerlin, Heidelberg101131 102BanN.The" exact="complete" post="atomic structure of the large ribosomal subunit at 2.4"/>
  <result pre="113SioudM.Application of preformed hammerhead ribozymes in the gene therapy of" exact="cancer" post="(review)Int. J. Mol. Med.34199938138410085409 114SenD.GeyerC.R.DNA enzymesCurr. Opin. Chem. Biol.2619986806879914188"/>
  <result pre="of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human" exact="immunodeficiency" post="virusProc. Natl. Acad. Sci. U. S. A.84211987770677103499613 117BennettC.F.Pharmacology of"/>
  <result pre="of antisense drugsAnnu. Rev. Pharmacol. Toxicol.5720178110527732800 118SasakiS.GuoS.Nucleic acid therapies for" exact="cystic" post="fibrosisNucleic Acid Ther.28120181929160746 119KoleR.KrainerA.R.AltmanS.RNA therapeutics: beyond RNA interference and"/>
  <result pre="interference and antisense oligonucleotidesNat. Rev. Drug Discov.112201212514022262036 120ZamecnikP.C.StephensonM.L.Inhibition of Rous" exact="sarcoma" post="virus replication and cell transformation by a specific oligodeoxynucleotideProc."/>
  <result pre="biology, diagnostics, and therapeuticsCurr. Opin. Chem. Biol.52201911212431541865 125WangZ.Inhibition of severe" exact="acute" post="respiratory syndrome virus replication by small interfering RNAs in"/>
  <result pre="diagnostics, and therapeuticsCurr. Opin. Chem. Biol.52201911212431541865 125WangZ.Inhibition of severe acute" exact="respiratory" post="syndrome virus replication by small interfering RNAs in mammalian"/>
  <result pre="and therapeuticsCurr. Opin. Chem. Biol.52201911212431541865 125WangZ.Inhibition of severe acute respiratory" exact="syndrome" post="virus replication by small interfering RNAs in mammalian cellsJ.Â"/>
  <result pre="interfering RNAs in mammalian cellsJ.Â Virol.781420047523752715220426 126SandersJ.M.Pharmacologic treatments for Coronavirus" exact="disease" post="2019 (COVID-19): a reviewJAMA2020 127TangT.Coronavirus membrane fusion mechanism offers"/>
  <result pre="target for antiviral developmentAntivir. Res.178202010479232272173 128PyrcK.Inhibition of human coronavirus NL63" exact="infection" post="at early stages of the replication cycleAntimicrob. Agents Chemother.50620062000200816723558"/>
  <result pre="DNA enzyme can specifically target the 5'-untranslated region of severe" exact="acute" post="respiratory syndrome associated coronavirus (SARS-CoV)J.Â Gene Med.91220071080108617966113 131AhnD.G.Interference of"/>
  <result pre="enzyme can specifically target the 5'-untranslated region of severe acute" exact="respiratory" post="syndrome associated coronavirus (SARS-CoV)J.Â Gene Med.91220071080108617966113 131AhnD.G.Interference of ribosomal"/>
  <result pre="can specifically target the 5'-untranslated region of severe acute respiratory" exact="syndrome" post="associated coronavirus (SARS-CoV)J.Â Gene Med.91220071080108617966113 131AhnD.G.Interference of ribosomal frameshifting"/>
  <result pre="coronavirus replicationAntivir. Res.911201111021549154 132JangK.J.Isolation of inhibitory RNA aptamers against severe" exact="acute" post="respiratory syndrome (SARS) coronavirus NTPase/HelicaseBiochem. Biophys. Res. Commun.3663200873874418082623 133SmithJ.LipsitchM.AlmondJ.W.Vaccine"/>
  <result pre="replicationAntivir. Res.911201111021549154 132JangK.J.Isolation of inhibitory RNA aptamers against severe acute" exact="respiratory" post="syndrome (SARS) coronavirus NTPase/HelicaseBiochem. Biophys. Res. Commun.3663200873874418082623 133SmithJ.LipsitchM.AlmondJ.W.Vaccine production,"/>
  <result pre="Res.911201111021549154 132JangK.J.Isolation of inhibitory RNA aptamers against severe acute respiratory" exact="syndrome" post="(SARS) coronavirus NTPase/HelicaseBiochem. Biophys. Res. Commun.3663200873874418082623 133SmithJ.LipsitchM.AlmondJ.W.Vaccine production, distribution,"/>
  <result pre="indications: a case study of a vaccine against rabiesVaccines742019132 144BioNTechInfectious" exact="Disease" post="Immunotherapies2020[cited 2020 May 28]; Available from:https://biontech.de/taxonomy/term/99 145Arcturus TherapeuticsArcturus Therapeutics"/>
  <result pre="how many envelope glycoprotein trimers per virion participate in human" exact="immunodeficiency" post="virus infectivity and its neutralization by antibodyVirology3692200724526217825343 151MagnusC.Estimating the"/>
  <result pre="and its neutralization by antibodyVirology3692200724526217825343 151MagnusC.Estimating the stoichiometry of human" exact="immunodeficiency" post="virus entryJ.Â Virol.83320091523153119019953 152WoutersO.J.McKeeM.LuytenJ.Estimated research and development investment needed"/>
  <result pre="versus global preparednessLancet Respir. Med.622018949529169772 161PardiN.WeissmanD.Nucleoside modified mRNA vaccines for" exact="infectious" post="diseasesMethods Mol. Biol.1499201710912127987145 162SchlakeT.mRNA as novel technology for passive"/>
  <result pre="naturally occurring and vaccine-induced CD4 and CD8 T cells in" exact="cancer" post="patientsCancer Immunol. Immunother.583200932533818663444 164LimB.LeeK.Stability of the osmoregulated promoter-derived proP"/>
  <result pre="vitro-transcribed mRNAs delivered by lipid nanoparticlesBiol. Pharm. Bull.422201929930230713260 167PeckK.M.LauringA.S.Complexities of" exact="viral" post="mutation ratesJ.Â Virol.92142018 168PepiniT.Induction of an IFN-mediated antiviral response"/>
  <result pre="172LiS.S.DNA priming increases frequency of T-cell responses to a vesicular" exact="stomatitis" post="virus HIV vaccine with specific enhancement of CD8+ T-cell"/>
  <result pre="IIEST Shibpur, Howrah, Motihari College of Engineering and Mahatma Gandhi" exact="Central" post="University Motihari, Bihar, respectively."/>
 </snippets>
</snippetsTree>
